Molina Healthcare Inc.

ticker: MOH step: 01 generated: 2026-05-13 source: quick-research

Molina Healthcare, Inc. (MOH) — Business Overview

Business Description

Molina Healthcare is a managed care organization (MCO) focused exclusively on government-sponsored health programs — Medicaid, Medicare, and Marketplace (ACA exchange) — serving approximately 5.6 million members across 19 states as of late 2025. The company contracts with state governments to provide managed care services to Medicaid enrollees (low-income individuals, families, disabled, and dual-eligible populations) in exchange for per-member-per-month (PMPM) capitation payments. FY2025 premium revenue was ~$43.1B (+11% YoY). Molina is the third-largest pure-play Medicaid managed care company in the U.S. after Centene and Anthem.

Revenue Model

Revenue is almost entirely premium-based: state governments pay Molina a fixed monthly capitation rate per enrolled member, and Molina manages the medical costs of that population. Profit is the spread between capitation received and medical costs paid (the Medical Care Ratio or MCR — ideally 85-90%). Revenue grows through three mechanisms: (1) membership growth from new contract wins and expansion in existing states, (2) annual rate increases from state governments tied to actuarial cost trends, and (3) acquisitions of other state MCOs. Revenue is highly predictable; profitability is sensitive to medical cost trends.

Products & Services

• Medicaid (~75-79% of premium revenue): Managed care for low-income adults, children (CHIP), and long-term services and supports (LTSS) for disabled/elderly. Pure capitated model.
• Medicare (~15%): Medicare Advantage plans for low-income seniors, including dual-eligible (Medicare + Medicaid) populations. D-SNP and LTSS products.
• Marketplace (~8-10%): ACA exchange plans in select states for subsidized low-to-moderate income individuals.
• Exiting Medicare Advantage Part D: ~$1B premium product being discontinued for 2027 due to underperformance.

Customer Base & Go-to-Market

State Medicaid agencies are Molina's direct customers — the company wins business through competitive RFP (request for proposal) processes, typically 5-7 year contracts with renewal options. Medicaid members are auto-assigned to plans or self-select. Molina competes in each state against Centene, Elevance (Anthem), UnitedHealth (UnitedHealthcare Community Plan), and regional plans. Contract retention is typically high (70-85%) but new state entries require significant upfront investment.

Competitive Position

Molina is the most pure-play government program MCO among large public companies — nearly 100% government program revenue versus Centene's 80%+ and Elevance's ~50%. This focus provides operational expertise in low-income populations, LTSS, and dual-eligible management that broader MCOs don't prioritize. The company has grown from a California-centric MCO to a national 19-state platform through systematic acquisitions. Recent Florida Medicaid contract win (statewide, ~120,000 members, ~$5B annual premium) was a major competitive win.

Key Facts

• Founded: 1980
• Headquarters: Long Beach, California
• Employees: ~20,000
• Exchange: NYSE
• Sector / Industry: Health Care / Managed Health Care
• Market Cap: ~$8B (down from ~$20B peak; stock down ~65% from 2023 highs)

ticker: MOH step: 04 generated: 2026-05-13 source: quick-research

Molina Healthcare, Inc. (MOH) — Financial Snapshot

Income Statement Summary

FY2022-FY2023: stable and profitable; MCR managed at ~88%. FY2024: Medicaid cost trends (acuity higher than expected post-COVID, redetermination of ineligible members slower than expected) drove MCR above 90%, compressing margins. FY2025: premium revenue $43.1B (+11%), but negative $535M operating cash flow — a serious deterioration. Q4 2025 reported a loss; FY2026 guidance sharply weaker than consensus.

Cash Flow & Balance Sheet (FY2024/2025)

Key Ratios (approximate)

• P/E: ~10x (on depressed 2026 guidance EPS) | EV/EBITDA: ~8x
• Revenue Growth (FY2025): +11% | Premium Revenue: $43.1B
• Net Margin: ~1.5% (at current MCR levels — thin spread business)
• Members: ~5.6M (Sep 2025)

Growth Profile

Molina grew revenue rapidly through 2022-2024 via contract wins (Florida, California expansions) and acquisitions. However, profitability has severely deteriorated: Medicaid MCRs rose above 90% (vs. sustainable ~88%) due to post-COVID utilization normalization, acuity increases in managed LTSS populations, retroactive California Medicaid adjustments, and state rate increases lagging cost trends. The company is in a trough — management's FY2026 guidance implies a recovery to positive cash flow as rates catch up. Medicare Advantage Part D exit (2027) removes ~$1B of an underperforming segment.

Forward Estimates

• FY2026 guidance: Significantly below prior Street estimates — caused 28% stock decline in Feb 2026
• Consensus Hold: 12 analysts; avg. price target ~$167 (modest upside from ~$145-150)
• Q1 2026 actual EPS: beat estimates, stock +9.1%; guidance included in update
• Recovery thesis: MCR normalization in 2027-2028 as state rates catch up to costs
• Risk: Medicaid FMAP federal match rate reductions being discussed in Congress

ticker: MOH step: 12 generated: 2026-05-13 source: quick-research

Molina Healthcare, Inc. (MOH) — Investment Catalysts & Risks

Bull Case Drivers

1. Medicaid Rate Catch-Up: 2026-2027 is the Recovery Inflection — Molina's profitability crisis is fundamentally a timing mismatch: medical costs rose faster than Medicaid capitation rates in 2024-2025, compressing MCRs above 90%. State Medicaid rate-setting is actuarially-based — rates trail costs by 12-18 months as states gather data before adjusting. Bulls argue that the rate lag is temporary: FY2026-FY2027 state rate increases are already incorporating the higher acuity and utilization data from 2024-2025. As rates catch up to costs, MCRs normalize back toward 88%, and Molina's operating margins recover toward historical targets. Q1 2026's +9.1% stock move on earnings confirms early signs of stabilization.

2. Florida Medicaid Contract Win is a Multi-Year Revenue Platform — Molina was awarded a statewide Florida Medicaid managed care contract covering ~120,000 enrollees with ~$5B in annual premium revenue. Florida is one of the largest Medicaid markets in the U.S. — winning a statewide sole-source position is a generational contract win. Premium revenue from Florida ramps through 2025-2027 and represents a significant incremental revenue stream at what should be normalized margins as the rate environment normalizes. Combined with California, Texas, Ohio, and New York positions, Molina's geographic diversification protects against any single-state contract risk.

3. Structural Medicaid Market Growth + Dual-Eligible Expansion — Medicaid enrollment grows structurally with U.S. population demographics and economic cycles. The dual-eligible population (individuals qualifying for both Medicaid and Medicare — typically low-income elderly and disabled) is the fastest-growing and highest-acuity managed care segment, generating substantially higher PMPM revenue than standard Medicaid. Molina has invested in D-SNP (Dual Special Needs Plan) capabilities — a specialized Medicare Advantage product for dual-eligible members — which represents a long-term high-margin growth vector. If managed care penetration of dual-eligible continues to expand through MLTSS (Managed Long-Term Services and Supports) mandates, Molina's specialized capabilities create competitive advantages.

Bear Case Risks

1. MCR Normalization May Take Longer Than Expected — Structural Cost Risk — The optimistic view assumes state rates catch up to costs in 2026-2027. The pessimistic view is that Medicaid cost trends have permanently shifted upward: post-COVID utilization catch-up in behavioral health, LTSS costs for aging members, and GLP-1 drug costs entering Medicaid formularies could keep MCRs structurally elevated above 90%. If Molina cannot get state rates to adequately cover actual costs — which requires successful actuarial negotiations in each of 19 states — the MCR compression is not a timing problem but a structural business model problem. The negative $535M operating cash flow in FY2025 is an alarming leading indicator.

2. Federal Medicaid Funding Cuts (FMAP Reduction) — Political Tail Risk — Congressional discussions about reducing the federal share of Medicaid costs (FMAP — Federal Medical Assistance Percentage) represent an existential risk to Medicaid managed care companies. If federal FMAP rates are cut, states receive less federal matching funding, which forces them to either reduce benefits, restrict eligibility, or reduce capitation payments to MCOs like Molina. Even a 1-2% reduction in FMAP could trigger state-level Medicaid contractions that directly reduce Molina's premium revenue and membership. This risk is not hypothetical — it has been an active topic in 2025-2026 congressional budget negotiations.

3. Rising Debt + Negative Cash Flow Raises Financial Stability Concerns — Total debt rose to $3.77B while operating cash flow turned negative (-$535M) in FY2025 — a combination that is unsustainable if it continues. Molina must fund operations through its cash reserves (~$4.5B, but much of this is state-regulated minimum capital) and potentially additional debt. If the MCR normalization takes 2-3 years longer than expected, the company may need to raise equity capital at depressed prices or restructure its debt — a risk that has caused significant multiple compression (stock down ~65% from 2023 highs). The Medicare Part D exit ($1B premium, ~$100-150M in annual losses) provides some cash flow relief in 2027 but not in 2025-2026.

Upcoming Events

• Q2 2026 Earnings: Critical read on whether MCR is normalizing — any improvement below 90% combined MCR would be a strong positive signal
• State Medicaid Rate Negotiations: Annual rate-setting cycles across 19 states — watch for news of above-trend rate increases as states incorporate higher utilization data
• Medicare Advantage Part D Exit: Operational execution of unwinding ~$1B in premium volume without disrupting member services or triggering regulatory action
• Congressional FMAP Action: Any legislation reducing federal Medicaid matching rates is a direct negative catalyst; any legislation protecting/expanding Medicaid is a positive

Analyst Sentiment

Consensus Hold (12 analysts); avg. price target ~$167 from recent ~$145-150 levels. Bulls see a trough recovery story — rate normalization restores margins by 2027, Florida contract ramp provides revenue, and the stock at ~10x depressed EPS is cheap if recovery materializes. Bears cite structural MCR risk, federal funding uncertainty, rising debt, and execution concerns on 19-state rate negotiations simultaneously. Stock down 65% from 2023 highs ($380) reflects severe erosion of the earnings power narrative.

Research Date

Generated: 2026-05-13